-
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
Monday, August 28, 2023 - 10:13am | 373Read More...Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, reported its financial results for Q2 2023. The company's CEO, Iris Bincovich, expressed excitement about the positive trajectory and strategic...
